Biochemistry, Genetics and Molecular Biology
Activating Transcription Factor 1
10%
Allele
30%
Binding Protein
11%
Carcinogenesis
20%
CD34
10%
Cell Cycle Progression
10%
Colony Formation
13%
CREB
17%
Cyclic Adenosine Monophosphate
18%
Cyclin-Dependent Kinase
14%
Cytogenetics
40%
Cytokine
10%
Dasatinib
25%
DNA Damage
10%
DNA Sequence
12%
Downregulation
12%
Drug Response
11%
Drug Sensitivity
13%
Eicosanoid Receptor
20%
Enhancer Region
10%
F-Box Protein
10%
Fibrinogen
10%
Functional Genomics
13%
G1/S Transition
10%
Gene Expression Profiling
11%
GRB2
10%
Hematopoietic Stem Cell
10%
Hepatocyte Growth Factor
10%
High Throughput Sequencing
15%
IC50
10%
Imatinib
30%
In Vitro Study
11%
Kinase
48%
Kinome
20%
Leucine Zipper
11%
Lymphoblast
10%
Mesylate
10%
Mouse
15%
Myeloid
100%
Philadelphia Chromosome
20%
Phosphotransferase
48%
Protein Kinase A
15%
Protein-Protein Interaction
10%
PTPN11
10%
Small Molecule
19%
Thymic Stromal Lymphopoietin
10%
Transcription
11%
Tumor Suppressor Protein
16%
Tyrosine
30%
Wild Type
14%
Keyphrases
Activating mutation
13%
Acute Lymphoblastic Leukemia
22%
Acute Myeloid Leukemia
40%
AP24534
20%
Atypical Chronic Myeloid Leukemia
12%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
15%
BCR-ABL
24%
BCR-ABL Inhibitors
10%
CAMP-dependent Protein Kinase
12%
Chronic Myeloid Leukemia
52%
Clear Cell Renal Cell Carcinoma (ccRCC)
10%
Cytogenetic Abnormalities
14%
Cytogenetic Response
13%
Dasatinib
22%
DNA Sequence Analysis
12%
Enhancer-binding Protein
10%
Fallopian Tube Occlusion
10%
FMS-like Tyrosine Kinase 3 (FLT3)
30%
Functional Assessment
12%
Hematological Malignancies
10%
High-throughput
12%
Imatinib
22%
Inflammatory Cytokines
11%
JAK2V617F
27%
JAK2V617F mutation
11%
Janus Kinase 2 (JAK2)
22%
Kinase Inhibition
11%
Kinome
20%
Leucine Zipper
12%
Leukemia
25%
Leukemia Patients
18%
Murine Model
11%
Myeloproliferative Neoplasms
35%
Philadelphia Chromosome
10%
Philadelphia Chromosome-negative
20%
Phosphorylation
22%
PI3K Signaling
10%
Platelet-derived Growth Factor Receptor (PDGFR)
12%
PTPN11
10%
ROR1
13%
Sequence Analysis
12%
Small Intestine Submucosa
13%
Small Molecule Inhibitors
17%
Stent-graft
20%
Swine
20%
TNK2
11%
Transcriptionally Active
10%
Transjugular Intrahepatic Portosystemic Shunt
16%
Tyrosine
10%
Tyrosine Kinase
12%
Medicine and Dentistry
Acute Graft Versus Host Disease
10%
Acute Lymphoblastic Leukemia
20%
Acute Myeloid Leukemia
45%
Allele
19%
Artery
15%
B Cell
15%
B Cell Signaling
10%
B-Cell Chronic Lymphocytic Leukemia
23%
Blood Clotting
10%
Blood Stasis
10%
Bortezomib
10%
Cancer
13%
Carcinoma Cell
10%
Catheterization
10%
Cell Viability
13%
Chronic Myelogenous Leukemia
50%
Chronic Myelogenous Leukemia
12%
Chronic Myelomonocytic Leukemia
13%
Chronic Neutrophilic Leukemia
16%
Colony Stimulating Factor 1
10%
Disease
20%
DNA Sequence
10%
Drug Response
11%
Femoral Artery
12%
Functional Assessment
10%
Functional Genomics
14%
Imatinib
16%
In Vitro
24%
Janus Kinase 2
12%
Leukemia Cell
27%
Leukemogenesis
13%
Mast Cell Leukemia
10%
Myeloproliferative Disorder
14%
Myeloproliferative Neoplasm
13%
Neoplasm
16%
Nephrostomy
10%
Phosphotransferase
19%
Politef
10%
Polyethylene Terephthalate
11%
Ponatinib
10%
Rhabdomyosarcoma
10%
Stem Cell
12%
Stent-Graft
21%
Submucosa
20%
Systemic Mastocytosis
10%
Target Identification
10%
Transjugular Intrahepatic Portosystemic Shunt
20%
Uterine Artery Embolization
10%
Uterine Tube Occlusion
10%
Venetoclax
10%
